HIV-1 Drug Resistance in Newly Infected Individuals

Open Access

22 September 1999

journal article
research article
Published by American Medical Association (AMA) in JAMA

Vol. 282 (12) , 1135-1141
https://doi.org/10.1001/jama.282.12.1135

Abstract

Therapy with combinations of antiretroviral drugs that inhibit the constitutive enzymes, human immunodeficiency virus 1 (HIV-1) protease and reverse transcriptase, dramatically reduce HIV-1 replication in vivo¹^-3 and have resulted in marked reductions in HIV-associated morbidity and mortality.⁴^,5

Keywords

This publication has 26 references indexed in Scilit:

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
AIDS, 1999
Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir
Antimicrobial Agents and Chemotherapy, 1998
Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients
Annals of Internal Medicine, 1998
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
New England Journal of Medicine, 1998
Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
AIDS, 1997
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
New England Journal of Medicine, 1997
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
New England Journal of Medicine, 1997
Decay characteristics of HIV-1-infected compartments during combination therapy
Nature, 1997
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Nature Medicine, 1996
Transmission of zidovudine-resistant HIV-1
AIDS, 1993